Implementation of the Lifecycle Approach to Process Validation Statistics
Maneesha Altekar, PhD
The ISPE 2016 Process Validation Statistics Conference is in its 3rd year, continuing with its successful tradition of bringing together pharmaceutical leaders within the industry and regulatory authorities to share their thoughts in the implementation of the lifecycle approach to process validation. The keynote talks are always inspiring – and this year is no exception:
The ISPE 2016 Process Validation Statistics Conference will feature:
Advances in statistical applications to process validation Stages 1-3 along with applications and case studies
Introducing attendees to newer concepts in process validation such as applications to Packaging and Continuous Manufacturing
Panel discussions at each session, which will allow for a more interactive opportunity for you to engage with the speakers and each other
Polling throughout the meeting that will provide invaluable benchmarking information for you and your organization
Networking breaks allowing for an opportunity to catch up with old colleagues and make new contacts
As always, there will be a mixed group of statisticians and process validation practitioners, representing every category of pharmaceutical manufacturing (small molecule, large molecule, devices, and more). For those of you who are not statisticians but want to know more about the statistics used in process validation and be better prepared for the conference sessions? There will be two 90-minute session on the first day of the conference to make you become better acquainted with some of the key topics that will be discussed during the sessions:
Maneesha Altekar is a Sr. Technical Manager for Product Robustness & Analytics at AstraZeneca, where she is currently working on the development and rollout of...
Are you considering joining ISPE? Or maybe you’ve recently joined the society or are a longtime member looking to better understand all the benefits available to you. If so, you’ve come to the right place!
ATMPs are based on genes, cells or tissues delivered to patients to provide a therapeutic benefit based on a specific target of interest. Often referred to as ‘Personalised Medicine’. A sector of healthcare that is rapidly evolving and expanding with some unique challenges such as microbial contamination and product variability. Traditional manufacturing processes are for synthetically derived...
GAMP® 5 Second Edition is here! Since its publication, GAMP® 5 has been far and away the leading international guidance on GxP computerized systems validation and compliance, and it was time to update our guidance to...